Search This Blog

Sunday, April 26, 2015

Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval (NYSE:LLY)

CYRAMZA Now Approved in the U.S. for Use with FOLFIRI in Second-Line Treatment of Metastatic Colorectal Cancer



Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.